Revimmune: " Rebooting" the Immune System

Accentia Biopharmaceuticals acquires worldwide exclusive license to Revimmune

This is an amazing sounding treatment, but bear in mind that it is still in late-stage development. Revimmune attempts to treat and potentially cure autoimmune diseases such as MS by “rebooting” the human immune system, and the rights to sell this compound have been acquired by Accentia Biopharmaceuticals (Nasdaq: ABPI). According to a press release linked below, the drug works by decimating peripheral immune cells, including those responsible for autoimmune responses like MS. Stem cells located in the bone marrow are spared however, and they reconstitute the immune system over a period of 2 to 3 weeks. Typically the reconstituted system lacks the misdirected autoimmunity, resulting in a reduction or elimination of disease progression. While MS will be Accentia’s lead indication for Revimmune, the article mentions many other autoimmune diseases including systemic lupus, juvenile diabetes mellitus, rheumatoid arthritis, Crohn’s disease, myasthenia gravis, and scleroderma.

http://brainspotting.org/